Melatonin and Cancer Hallmarks DOI Creative Commons
Wamidh H. Talib

Molecules, Journal Year: 2018, Volume and Issue: 23(3), P. 518 - 518

Published: Feb. 26, 2018

Melatonin is a natural indoleamine produced by the pineal gland that has many functions, including regulation of circadian rhythm. Many studies have reported anticancer effect melatonin against myriad cancer types. Cancer hallmarks include sustained proliferation, evading growth suppressors, metastasis, replicative immortality, angiogenesis, resisting cell death, altered cellular energetics, and immune evasion. activity mediated interfering with various hallmarks. This review summarizes role in each hallmark. The discussed this should serve as solid foundation for researchers physicians to support basic clinical on promising agent.

Language: Английский

Cell cycle control in cancer DOI
Helen K. Matthews, Cosetta Bertoli, Robertus A.M. de Bruin

et al.

Nature Reviews Molecular Cell Biology, Journal Year: 2021, Volume and Issue: 23(1), P. 74 - 88

Published: Sept. 10, 2021

Language: Английский

Citations

965

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes DOI
Robert Roskoski

Pharmacological Research, Journal Year: 2015, Volume and Issue: 103, P. 26 - 48

Published: Nov. 4, 2015

Language: Английский

Citations

713

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation DOI
Calla M. Olson,

Baishan Jiang,

Michael A. Erb

et al.

Nature Chemical Biology, Journal Year: 2017, Volume and Issue: 14(2), P. 163 - 170

Published: Dec. 18, 2017

Language: Английский

Citations

465

Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases DOI
Per Hydbring, Marcos Malumbres, Piotr Siciński

et al.

Nature Reviews Molecular Cell Biology, Journal Year: 2016, Volume and Issue: 17(5), P. 280 - 292

Published: April 1, 2016

Language: Английский

Citations

458

The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer DOI Open Access
Lei Ding,

Jiaqi Cao,

Wen-Shan Lin

et al.

International Journal of Molecular Sciences, Journal Year: 2020, Volume and Issue: 21(6), P. 1960 - 1960

Published: March 13, 2020

Cyclin-dependent kinases (CDKs) are serine/threonine whose catalytic activities regulated by interactions with cyclins and CDK inhibitors (CKIs). CDKs key regulatory enzymes involved in cell proliferation through regulating cell-cycle checkpoints transcriptional events response to extracellular intracellular signals. Not surprisingly, the dysregulation of is a hallmark cancers, inhibition specific members considered an attractive target cancer therapy. In breast (BC), dual CDK4/6 inhibitors, palbociclib, ribociclib, abemaciclib, combined other agents, were approved Food Drug Administration (FDA) recently for treatment hormone receptor positive (HR+) advanced or metastatic (A/MBC), as well sub-types cancer. Furthermore, ongoing studies identified more selective promising clinical targets. this review, we focus on roles driving progression, checkpoints, regulation, highlight dysregulated activation BC. We also discuss most relevant currently BC trials, special emphasis used estrogen receptor-positive (ER+)/human epidermal growth factor 2-negative (HER2−) M/ABC patients, emerging precise therapeutic strategies, such combination therapies microRNA (miRNA)

Language: Английский

Citations

453

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance DOI Open Access
Ping Chen,

Nathan V. Lee,

Wenyue Hu

et al.

Molecular Cancer Therapeutics, Journal Year: 2016, Volume and Issue: 15(10), P. 2273 - 2281

Published: Aug. 6, 2016

Abstract Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development often hindered by toxicities and inadequate efficacy. Predicting behaviors using cellular animal models confounded redundant activities, lack of unique substrates, cell-specific networks. Cyclin-dependent (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clinical activities. Tumor cell studies ATP-competitive CDK (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacology while analyses in untransformed cells illuminates significant differences. To resolve apparent disconnect, described at the molecular level. Nonkinase binding kinome interaction analysis (recombinant endogenous kinases) reveal that proteins outside family appear little role dinaciclib/palbociclib/ribociclib pharmacology, may contribute for confounds AG-024322 analysis. CDK2 CDK6 cocrystal structures with identify interactions responsible potency selectivity. Efficient hinge architecture CDKs enables selectivity toward most human kinome. Selectivity between members achieved through nonconserved elements ATP-binding pocket. Integrating exposures into predicts both palbociclib ribociclib CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, dinaciclib broad-spectrum inhibitor (CDK2/3/4/6/9). Understanding components also facilitates rational design future generations kinase-directed drugs. Mol Cancer Ther; 15(10); 2273–81. ©2016 AACR.

Language: Английский

Citations

371

Signaling Pathways that Control Cell Proliferation DOI Open Access
Robert J. Duronio, Yuan Xiong

Cold Spring Harbor Perspectives in Biology, Journal Year: 2013, Volume and Issue: 5(3), P. a008904 - a008904

Published: March 1, 2013

Robert J. Duronio1,2,3 and Yue Xiong2,3,4 1Department of Biology Genetics, University North Carolina, Chapel Hill, Carolina 27599 2Program in Molecular Biotechnology, 3Lineberger Comprehensive Cancer Center, 4Department Biochemistry Biophysics, Correspondence: duronio{at}med.unc.edu; yxiong{at}email.unc.edu

Language: Английский

Citations

341

The Mediator complex and transcription regulation DOI Creative Commons

Zachary C. Poss,

Christopher C. Ebmeier, Dylan J. Taatjes

et al.

Critical Reviews in Biochemistry and Molecular Biology, Journal Year: 2013, Volume and Issue: 48(6), P. 575 - 608

Published: Oct. 3, 2013

The Mediator complex is a multi-subunit assembly that appears to be required for regulating expression of most RNA polymerase II (pol II) transcripts, which include protein-coding and non-coding genes. pol function within the pre-initiation (PIC), consists Mediator, II, TFIIA, TFIIB, TFIID, TFIIE, TFIIF TFIIH approximately 4.0 MDa in size. serves as central scaffold PIC helps regulate activity ways remain poorly understood. also generally targeted by sequence-specific, DNA-binding transcription factors (TFs) work control gene programs response developmental or environmental cues. At basic level, functions relaying signals from TFs directly enzyme, thereby facilitating TF-dependent regulation expression. Thus, essential converting biological inputs (communicated TFs) physiological responses (via changes expression). In this review, we summarize an expansive body research on complex, with emphasis yeast mammalian complexes. We focus basics underlie function, such its structure subunit composition, describe broad regulatory influence expression, ranging chromatin architecture initiation elongation, mRNA processing. activity, including TFs, RNAs CDK8 module.

Language: Английский

Citations

338

Inhibitors of cyclin-dependent kinases as cancer therapeutics DOI
Steven R. Whittaker,

Aurélie Mallinger,

Paul Workman

et al.

Pharmacology & Therapeutics, Journal Year: 2017, Volume and Issue: 173, P. 83 - 105

Published: Feb. 5, 2017

Language: Английский

Citations

336

Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs DOI
Robert Roskoski

Pharmacological Research, Journal Year: 2018, Volume and Issue: 139, P. 471 - 488

Published: Nov. 30, 2018

Language: Английский

Citations

327